Hiku Brands Company Ltd. (CSE:HIKU,OTCUS:DJACF) (“Hiku” or the “Company”) is pleased to announce the filing of its financial statements and management discussion and analysis for the fiscal year ending December 31, 2017. These filings are available for review on SEDAR.

“2017 was a transformational year as we worked to establish a solid foundation for Hiku leading into Canada’supcoming legalization of adult use cannabis,” said Alan Gertner, CEO of Hiku Brands. “In 2018, Hiku continues its mission to add to its portfolio of iconic brands, grow its retail footprint and enter into partnerships to advance the vision of becoming the preeminent vertically integrated cannabis brand house. With our recently announced merger with WeedMD, Hiku will immediately add 1,500 kg of indoor annual cannabis production capacity, fully funded production expansion capacity of more than 50,000 kg/yr and a well known, highly regarded medicinal brand. From our products to our in-store experiences, the combined company is poised to be a formidable force in the cannabis industry.”


Fiscal Year 2017 Highlights

June

  • Received License to Cultivate – Hiku’s wholly-owned subsidiary, DOJA Cannabis Ltd. (“DOJA”), received its license to cultivate under the ACMPR (Access to Cannabis for Medical Purposes Regulations) from Health Canada;

August

  • Go-public – Completed a go-public transaction on the Canadian Securities Exchange

October

  • Completed First Harvest – Harvested and cured DOJA’s first batches of premium handcrafted cannabis flower in October at its Dominion facility in West Kelowna, British Columbia (with annual production capacity of 660 kg of dried flower);
  • First DOJA Cafe Opened – Opened the first DOJA Cafe, a retail store in downtown Kelowna, focused on building brand awareness, cannabis education, and medical patient pre-registration. The location is non-cannabis dispensing and sells artisanal coffee, clothing and accessories;
  • Secured Expansion Property – Purchased a building and land out of receivership in Kelowna, British Columbia, home to DOJA’s second site facility (the “FUTURE LAB”), which is anticipated to expand annual corporate production capacity by an additional 4,500 kg;

November

  • FUTURE LAB Construction – Commenced construction on the FUTURE LAB, the facility will incorporate solar power, LED lighting, two-tier vertical farming and a state-of-the-art extraction lab;

December

  • Imported Cannabis Seeds – Received an import permit from Health Canada for cannabis seeds to build DOJA’s genetics library to differentiate the brand, not only through its products and approach to the market, but also by curating a diverse and proprietary cultivar offering;
  • Raised $20 Million – Strengthened the Company’s balance sheet by a total of $20 million through equity and convertible debt financings;
  • DOJA & Tokyo Smoke Merger – Announced a transformational merger of DOJA and TS Brandco Holdings Ltd. (“Tokyo Smoke”), bringing together industry leading management teams, British Columbia curated handcrafted cannabis production, a portfolio of visionary brands and a growing nationwide retail footprint; and
  • Aphria Strategic Investment – Announced a strategic financing of $12.5 million led by Aphria Inc. (Hiku subsequently closed the financing on January 9, 2018.)

2018 Highlights to Date

January

  • Launched Hiku – The merger of DOJA and Tokyo Smoke closed and the combined company was renamed Hiku Brands Company Ltd. – becoming Canada’s first vertically integrated cannabis brand house and uniting the cannabis brands DOJATokyo Smoke, and Van der Pop;

February

  • Added Quebec Brand – Hiku signed a binding LOI with Maïtri Group Inc, a Quebec based cannabis brand, to acquire 100% of the issued and outstanding shares (Hiku subsequently entered into the definitive agreement on April 30);
  • Awarded Manitoba Retail License – Tokyo Smoke, with participation of BOBHQ, was conditionally awarded one of four master retail licenses in Manitoba’s Request for Proposal process for the right to operate retail cannabis stores. The license gives Tokyo Smoke the ability to operate legal retail cannabis stores and an online cannabis e-commerce platform in Manitoba;
  • Entered into First International Partnership in Jamaica – Hiku entered into a LOI with Kaya Inc., the first licensed medical cannabis producer and dispensary operator in Jamaica, to launch a strategic alliance to pursue medical and adult-use cannabis branding, genetics, and retail opportunities in Jamaica and Canada;

March

  • Announced Cannabis Oil Partnership – Signed a strategic partnership agreement with Vitalis Extraction Technology Inc., a Kelowna based company at the forefront of CO2 extraction innovation;
  • Bolstered Leadership Team – Made several key additions to the leadership team with significant expertise in retail, branding, government relations and communications;
  • Redefining the Cannabis Retail Experience – Entered into an exclusive collaboration agreement with Jackman Reinvention Inc. (a strategic and creative brand consultancy with deep experience in retail execution) to create a blueprint for Hiku’s dispensary build-outs in select provinces;
  • Bringing Exceptional Products to Market – Entered into a letter of intent to establish a co-marketing, retail and select distribution relationship with dosist (previously known as hmbldt), a leading wellness brand providing consistent, controlled and effective cannabis-based solutions

April

  • Received Sales License – DOJA received an amendment to its sales license from Health Canada to include the sales of dried cannabis, cannabis plants and seeds; and
  • Hiku & WeedMD Merger – Hiku entered into a definitive agreement to merge with WeedMD, combining a premium cannabis brand house and retail focused operator in Hiku, with the significant production capabilities and differentiated medical brand in WeedMD. The combined company will have a diversified cannabis cultivation platform with four facilities from coast-to-coast with planned expansion capacity to have the ability to produce over 56,000 kg by mid-2019.

Definitive Agreement with Maïtri

Further to the press release dated February 1, 2018, Hiku is pleased to announce it has entered into a definitive share purchase agreement (the “Share Purchase Agreement”) to acquire 100% of the issued and outstanding shares ofMaïtri Group Inc. (“Maïtri”), a Quebec-based cannabis accessory and design brand (the “Acquisition”).

Pursuant to the Share Purchase Agreement, shareholders of Maïtri will receive upfront consideration of an aggregate of $550,000 in a combination of $50,000 cash and 318,471 Hiku shares (the “Consideration Shares”), and may earn up to an additional 764,329 Hiku shares in earn out and contingent payments if certain performance milestones are met. A portion of the Consideration Shares will be held in escrow and released to the shareholders of Maïtri over twenty-four months following the closing of the Acquisition. The parties intend to proceed to close the Acquisition as soon as possible and in accordance with the Canadian Securities Exchange policies.

About Hiku Brands

Hiku is focused on building a portfolio of engaging cannabis brands, unsurpassed retail experiences and handcrafted cannabis production. With a national retail footprint led by Tokyo Smoke, craft cannabis production through DOJA’s ACMPR licensed grow, and Van der Pop’s female-focused educational platforms, Hiku houses an industry-leading portfolio that aims to set the bar for cannabis brands in Canada.

Hiku’s wholly-owned subsidiary, DOJA Cannabis Ltd., is a federally licensed to cultivate and sell cannabis pursuant to the ACMPR, owning two production facilities in the heart of British Columbia’s Okanagan Valley. Hiku’s wholly-owned subsidiary, Tokyo Smoke has been conditionally awarded one of four master retail licenses in Manitoba. Hiku also operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

Forward-looking statements

This news release contains statements that constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Hiku’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.

Forward-looking statements in this document include, among others, the Company’s expectations concerning the completion of the merger with WeedMD and the planned production capacity of the combined company. By their nature, forward-looking statements are based on the opinions and estimates of management at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Hiku is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.

Click here to connect with Hiku Brands Company Ltd. (CSE: HIKU) for an Investor Presentation.

Source: www.newswire.ca

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less